Outlook Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
OTLK Nasdaq 8731 https://outlooktherapeutics.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Outlook Therapeutics Inc

Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million - Apr 15th, 2024 8:15 pm
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential - Apr 15th, 2024 4:54 pm
Insiders are Piling into These 10 Healthcare Stocks in 2024 - Apr 10th, 2024 7:30 pm
Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD - Mar 22nd, 2024 11:35 am
Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million - Mar 18th, 2024 9:10 pm
Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split - Mar 12th, 2024 12:05 pm
7 of the Best Speculative Stocks You Can Snag for Less Than $1 - Mar 6th, 2024 8:36 pm
7 Biotech Penny Stocks on the Verge of Clinical Trial Victory - Feb 25th, 2024 6:37 pm
Outlook Therapeutics Inc (OTLK) Reports Q1 Fiscal 2024 Results and Strategic Developments - Feb 14th, 2024 10:27 pm
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update - Feb 14th, 2024 1:05 pm
Outlook Therapeutics® Doses First Subject in NORSE EIGHT - Jan 31st, 2024 1:05 pm
Outlook (OTLK) Surges 31% on Regulatory Update for AMD Study - Jan 24th, 2024 1:06 pm
Outlook Therapeutics® Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-Inferiority Study, NORSE EIGHT, and Announces Private Placement of Up to $172 Million to Advance ONS-5010 - Jan 23rd, 2024 1:00 pm
Outlook Therapeutics® Reports Financial Results for Fiscal Year 2023 and Reiterates ONS-5010 Clinical and Regulatory Path Forward in the U.S. and EU - Dec 22nd, 2023 1:05 pm
Outlook Therapeutics® Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ONS-5010 - Dec 19th, 2023 1:05 pm
Outlook Therapeutics® Announces Strategic Organizational Realignment - Dec 6th, 2023 1:05 pm
Loss-Making Outlook Therapeutics, Inc. (NASDAQ:OTLK) Expected To Breakeven In The Medium-Term - Nov 28th, 2023 11:02 am
Outlook Therapeutics® Announces Receipt of Type A Meeting Minutes and Reiterates Regulatory Path Forward for ONS-5010 - Nov 27th, 2023 1:05 pm
Outlook Therapeutics® Adds Global Commercial Expertise with Appointment of Jedd Comiskey as Senior VP - Head of Europe - Nov 14th, 2023 1:05 pm
12 Best Day Trading Stocks To Buy - Nov 9th, 2023 1:52 pm